Orchard Therapeutics plc
ORTXDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Peg-Ada
Adenosine Deaminase Deficiency
PEG-ADA ERT
Severe Combined Immunodeficiency Due to ADA Deficiency
Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
Mucopolysaccharidosis Type IIIA
busulfan
ADA-SCID
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Peg-Ada | Phase 2 | Adenosine Deaminase Deficiency | - | - |
PEG-ADA ERT | Phase 2 | Severe Combined Immunodeficiency Due to ADA Deficiency | - | - |
Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene | Phase 2 | Mucopolysaccharidosis Type IIIA | - | - |
busulfan | Phase 2 | ADA-SCID | - | - |
Frequently asked questions
What is in Orchard Therapeutics plc's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Orchard Therapeutics plc's (ORTX) pipeline across Phase 2. Its lead program is Peg-Ada (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Orchard Therapeutics plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Orchard Therapeutics plc (ORTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ORTX biotech catalysts?→
Add ORTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Orchard Therapeutics plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.